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unctional testing (FT) for patients with chest pain has been a preferred method for evaluation of coronary artery disease (CAD) for decades. Current guidelines recommend FT to risk-stratify and identify patients with ischemia before invasive coronary angiography (ICA). However, as lower-probability patients are being referred, the prognostic and diagnostic accuracy of FT has declined. [1] [2] [3] Rozanski et al 4 demonstrated that the prevalence of abnormal single-photon emission computed tomography studies declined from 41% to only 9% over 2 decades. Patients with lower pretest probability being tested may have led to poorer performance of FT, especially for the diagnosis of obstructive CAD. Currently, a majority of patients who undergo ICA after FT have nonobstructive CAD or normal coronary arteries, confirming a low diagnostic accuracy in current clinical practice. 5 Of the patients enrolled in the National Cardiovascular Data Registry who had positive stress tests, 59% were found to have normal or nonobstructive disease at the time of ICA, slightly better than the 65% negative rate of those receiving ICA without previous stress testing. 6 In another National Cardiovascular Data Registry analysis of 302 651 single-photon emission computed tomography studies, only 134 670 (44.4%) had obstructive disease at ICA. 5 Exercise treadmill testing, stress echocardiography, and magnetic resonance also yielded very low (44%-45%) rates of obstructive CAD at the time of ICA. This performance of FT in current practice calls for evaluation of alternative strategies for the initial workup of patients who are presently at lower risk for myocardial ischemia and who have very low event rates given contemporary care. 7 These alternative strategies could also include no testing.
Coronary artery calcium (CAC) is a low-cost (typically <$100) and low-radiation (<1 mSv) test that allows direct visualization of coronary atherosclerosis without needles, contrast, or injection. 8 According to the most recent American Heart Association 9 and American College of Cardiology/American Heart Association 10 guidelines, CAC has Class IIA and IIB recommendations for assessing risk in intermediate-risk and low-to intermediate-risk asymptomatic patients, respectively, and in guiding management of hyperlipidemia. 11 Studies also indicate that CAC may accurately risk stratify for both low-risk stable patients with new-onset chest pain 12, 13 and those presenting to the emergency department with acute chest pain, and CAC has a Class IIB recommendation for use in symptomatic individuals. 9, 14 It should be noted that CAC does not test for obstructive disease or functional ischemia but rather is a surrogate for coronary atherosclerotic plaque burden. A low plaque burden in symptomatic individuals has been shown to be associated with a low-risk state and has been used in symptomatic individuals to predict a lowrisk state with absent or minimal CAC. However, most studies of CAC in symptomatic patients were limited by relatively small numbers of patients and limited followup. No large-scale or randomized study has evaluated the utility or prognostic ability of CAC in stable CAD compared with FT.
The PROMISE trial (Prospective Multicenter Imaging Study for Evaluation of Chest Pain) has published the prognostic implications of FT compared to coronary computed tomographic angiography (CTA). 7, 15 We have recently published a substudy of PROMISE comparing coronary CTA with FT. 16 Coronary CTA, by visualizing nonobstructive CAD, identifies additional at-risk patients and imparts better prognostic and discriminatory information than FT. Here, we present unique data evaluating prognostic data related to CAC in the PROMISE trial. We hypothesize that coronary atherosclerosis burden, as determined by CAC, will be a robust predictor of major adverse cardiovascular events (MACEs). We sought to evaluate the comparative prognostic ability of FT and CAC in a large cohort of symptomatic low-to intermediate-risk patients. 
METHODS

Study Design and Population
What Are the Clinical Implications?
• This study provides comparative evidence on the relative prognostic value of functional testing and CAC in a large stable chest pain population • This may improve the use of this information to guide management of these patients.
• A normal CAC score has a very low event rate, and may be used to avoid further cardiac testing in a stable chest pain population.
• An abnormal functional test result, including information on exercise, and symptoms, has moderate prognostic value.
• Coronary computed tomography angiography provides better prognostic and discriminatory power than either CAC or functional testing.
10 003 patients at 193 sites in North America with expertise in the fields of cardiology, primary care, radiology, and anesthesia and representing both community practices and academic medical centers. Details on the PROMISE study population, selection criteria, design, and primary results have been given elsewhere. 6, 15 The study participants were stable symptomatic outpatients without known CAD who were randomized to either anatomic or functional noninvasive cardiovascular testing for further evaluation. The methods for FT results classification and prognostic performance have recently been published by Hoffmann et al 16 in an analysis comparing FT with CTA. For this analysis, we included patients who received the initial diagnostic test as randomized. We excluded subjects who received other tests as their first test, did not undergo any diagnostic test, or did not receive a noncontrast study as part of their CTA. Of the 4996 patients who were randomized to the initial anatomic testing arm (CTA), 4209 underwent CAC testing. This number included those who received a noncontrast computed tomography (CT) only. Of the 4996 who were randomized to anatomic imaging (CTA), 154 received a different test other than CT first, 156 did not receive any testing despite randomization to anatomic imaging, and 477 did not receive CAC during the CTA. PROMISE was set up as a pragmatic study of CTA versus FT, and CAC was not specified as a part of the scanning algorithm, but 90% of patients who underwent CTA also had a CAC test and are included in this analysis.
For the FT group, we excluded patients whose test results could not be assigned to prespecified test strata because of indeterminate test results, including patients who underwent FT with exercise but achieved <75% of maximum predicted heart rate. The flow of patients is described in Figure 1 .
Study Procedures
After providing written informed consent, participants were randomly assigned to either the anatomic or the FT group, with stratification according to study site and according to the choice, as indicated before randomization by the site clinician, of the intended FT if the patient were to be assigned to that study group. 6 FT included exercise ECG, exercise or pharmacological nuclear myocardial perfusion imaging, and exercise or pharmacological stress echocardiography. CAC or CTA was performed with at least 64-slice multidetector computed tomographic technology. Not all patients received CAC as part of the anatomic testing. This was a pragmatic study in which the protocol required CTA testing without specifying whether CAC needed to be done as part of that examination. Thus, each site was able to decide whether to include CAC at the time of scan. The information related to exclusion of patients, the FT categories, and all interpretations were based on site interpretations and have been described in detail previously. 16 
Diagnostic Test Results
We defined a positive CAC to be one that showed coronary calcium (Agatston score >0). 17 An exercise ECG was considered positive if there were ST-segment changes consistent with ischemia during stress or early termination (<3 minutes) resulting from reproduction of symptoms, arrhythmia, or hypotension. A stress echocardiography or stress nuclear test was considered positive if there was any inducible ischemia in at least 1 coronary territory (anterior, inferior, or lateral) or early termination of exercise stress (<3 minutes) as a result of ST-segment changes consistent with ischemia, symptom reproduction, arrhythmia, or hypotension.
To further evaluate differences in test performance between FT and CAC testing, we stratified normal tests into completely normal, defined as CAC score of 0, normal ECG, absence of symptoms during exercise, normal exercise duration, and normal imaging (absence of any findings suggesting myocardial abnormalities, including fixed perfusion defects), and mildly abnormal, defined as the presence of any abnormalities not representing obstructive CAD or myocardial ischemia (CAC score of 1-99, late positive treadmill, abnormal ECG, or fixed defects for functional imaging). A more detailed description of the classification of test results is provided in Table 1 . The FT cutoff values have previously been published. 16 We also chose Figure 1 . Inclusion criteria.
to evaluate 2 different CAC cut points of interest, a score of >400 and >300 for severe abnormality (as defined by American College of Cardiology/American Heart Association 2013 guidelines). We further evaluated the performance of scores of 0 (to define appropriate use criteria of 0), <10 (inclusive of zero), and >10 as prespecified points of interest clinically.
Cardiovascular Risk Factors
Patient demographics and traditional cardiovascular risk factors were assessed and documented in a standard fashion at the time of enrollment in the PROMISE trial.
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Study End Points
The primary end point was a composite of time to MACEs, including death resulting from any cause, myocardial infarction, or hospitalization for unstable angina. The secondary end point was defined as a composite of cardiovascular death, myocardial infarction, or hospitalization for unstable angina, and the tertiary end point was a composite of cardiovascular death or myocardial infarction. An independent clinical events committee adjudicated all primary and secondary end point events in a blinded fashion on the basis of standard, prospectively determined definitions.
7,15
Statistical Analysis
Descriptive statistics are presented as mean and SD for continuous variables and absolute and relative frequencies for categorical variables. Cumulative event rates based on test results were computed for each testing strategy (CAC and FT) with the Kaplan-Meier method. 18 Cox proportional hazards regression models were used to compute hazard ratios (HRs) and 95% confidence intervals (CIs) for the relation of test results to the time to the first clinical event (or censoring) for each composite end point. 19 To appropriately account for heterogeneity among subjects, analyses were adjusted for a prespecified set of baseline covariates, including age, sex, and CAD risk equivalent (history of diabetes mellitus, peripheral artery disease, or cerebrovascular disease), and the prespecification of the intended FT (if randomly assigned to the FT arm). Proportional hazards assumption was tested on the basis of Schoenfeld residuals. To evaluate the predictive power of the Cox regression models, we computed the Harrell C (C statistic). 20, 21 Analyses were performed for the primary, secondary, and tertiary end points. All P values are 2 sided and were considered significant if <0.05. All analyses were performed with Stata, version 14.2 (StataCorp, College Station, TX). To standardize test reporting, site-reported test results were abstracted by a cardiology faculty or senior fellow physician using a prospectively designed protocol to deal with ambiguous test results, thereby standardizing interpretation of ambiguous test reports and harmonizing data across imaging modalities. For secondary risk stratification, mildly abnormal was defined as <70% luminal narrowing. CAC indicates coronary artery calcium; CAD, coronary artery disease; EF, ejection fraction; FT, functional testing; LAD, left anterior descending; MPI, myocardial perfusion imaging; and TM, treadmill.
*As defined by Hoffmann et al.
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RESULTS
Of the patients included, 4209 received CAC testing and 4602 received FT. The baseline demographics and risk factors are outlined in Table 2 . There were no clinically meaningful differences in baseline patient demographics, cardiovascular risk, medications, or clinical presentation between CAC and FT patients (Table 2) . Overall, patients were on average 61 years of age; slightly more than 50% were women; 78% were white; and the combined Diamond-Forrester and Coronary Artery Surgery Score was 53 in both groups. Approximately 51% were intermediate risk by Framingham Risk score (6%-20%), and 73% presented with chest pain, of whom 78% were described as having atypical angina. Plus-minus values are mean±SD. *Racial or ethnic minority group was self-reported, with the status of minority being defined by the patient.
†BMI is the weight in kilograms divided by the square of the height in meters.
‡A family history of premature coronary artery disease was defined as diagnosis of the disease in a male first-degree relative before 55 years of age or in a female first-degree relative before 65 years of age.
§Coronary artery disease risk equivalent was defined as diabetes mellitus, peripheral vascular disease, or cerebrovascular disease.
‖The metabolic syndrome was defined according to consensus criteria of the American Heart Association and the National Heart, Lung, and Blood Institute.
¶Sedentary lifestyle was defined by the patient as not participating in regular physical activities at least 1 time per week over the previous month.
#Risk factors included hypertension, diabetes mellitus, dyslipidemia, family history of premature coronary artery disease, and tobacco use. **Combined Diamond and Forrester and Coronary Artery Surgery Study risk scores range from 0 to 100, with higher scores indicating a greater likelihood of obstructive coronary artery disease.
† †The type of angina was reported by the study site investigators. Table 3 ).
An abnormal FT was significantly more specific for predicting events (78.6% for FT versus 35.2% for CAC; P<0.001; Table I in the online-only Data Supplement). Increasing the CAC cut point improved specificity, but at the expense of sensitivity. A cut point of ≥100 increased specificity to 67% while reducing sensitivity to 61%, and a CAC cut point of >400 revealed a specificity of 85% while lowering sensitivity to 31%.
Testing and Outcomes
Increasing CAC scores were associated with increasing risk of MACEs. A CAC score of zero was associated with a very low event rate (21 of 1457, 1.4%). Event rates (MACEs) increased with increasing CAC scores, with scores of 100 to 400 associated with a 5.2% event rate, increasing to 6.4% (41 of 640) in those with scores >400 (Table 3) . A normal FT was associated with a 2.1% event rate (75 of 3588), increasing to 9.6% in those with severe abnormalities. Similar results were found if events were defined as cardiovascular death/ myocardial infarction/unstable angina or cardiovascular death/myocardial infarction (Table 3) .
For both CAC and FT, severely abnormal test results were associated with a significantly increased relative risk for cardiovascular events for the primary end point compared with normal tests (HR, 3.56 [95% CI, 1.99-6.36] for CAC score >400 versus HR, 3.88 [95% CI, 2.58-5.85] for severe FT abnormality; P<0.001 for both) and for secondary end points and hard cardiovascular events (Table 3 and Figure 2 ).
Distribution of Events Based on CAC and FT Abnormalities
The distributions of events between the groups were quite different between testing strategies. A positive CAC test (CAC score >0) identified 112 of 133 total events (84.2%) and 44 of 53 hard events (83.0%), whereas a positive FT identified only 57 of 132 events (43.2%) of total death, myocardial infarction, and unstable angina and only 33.3% of hard cardiovascular events (myocardial infarction and cardiovascular death; Table 3 ). Overall, a negative FT had a low overall event rate (<1% annual cardiovascular event risk) and higher specificity for events than CAC. From a perspective of absolute risk, the majority of events occurred in patients with completely normal FT 
Discriminatory Ability
On the basis of this result, we further characterized the test results of patients who did not have an abnormal test, defined as significant CAC (score ≥100; n=2797) or myocardial ischemia (n=4020). CAC scanning identified 47.9% (n=1340 of 2797) of patients as having mild CAC (defined as a score of 1-99), and a minority of events occurred in these patients (23.3%, n=31 of 133; Table 3 ). Combining all normal and mild CAC represented 39.1% of events (52 of 133). In contrast, only 10.7% (n=432 of 4020) of patients in the FT arm had mildly abnormal tests (defined as presence of any abnormalities not representing myocardial ischemia, including late positive treadmill, abnormal ECG, or fixed defects; Table 1 ), and the majority of events (63.6%, n=84 of 132) occurred in those with mild or completely normal functional tests. Similar findings were seen for the end points of cardiovascular death/myocardial infarction/unstable angina and cardiovascular death/myocardial infarction ( 
CAC Compared With CTA
When test findings were stratified as mildly, moderately, or severely abnormal, HRs for events compared with normal tests increased proportionally for CTA and CAC testing, whereas HRs were higher for CTA (CTA: 2.94, 7.67, and 10.13, all P<0.001; CAC: 1.51 [P=0.147], 3.14, and 3.56 [both P<0.001]). In regard to obstructive disease, this study revealed that of those with zero CAC (n=1457), only 22 had stenosis ≥50% (Table 5 ). Of those with CAC=0, only 7 (0.5%) had >70% stenosis, 15 (1.0%) had 50% to 70% stenosis, 241 (14.7%) had nonobstructive stenosis, and 1177 (80.8%) had normal coronary arteries (zero stenosis) on coronary CTA.
DISCUSSION
The optimal diagnostic evaluation of patients suspected of having obstructive CAD remains unclear. Given the low prevalence of CAD and excellent prognosis of symptomatic patients with contemporary care, we sought to evaluate whether CAC might provide more robust prognostic information in this cohort than it does in asymptomatic populations. The results of this study demonstrate that CAC can robustly predict events in symptomatic individuals (HR 2.0-4.7) with results similar to FT. The study establishes, for the first time in a large prospective trial, the ability of zero CAC to predict a very low rate of future events in symptomatic patients and, more important, the safety of a zero score to exclude future cardiovascular events. 22 Similar to data in asymptomatic patients, this cohort demonstrates that a CAC=0 effectively excludes future cardiovascular events with <1% annual risk.
Several studies have been performed to evaluate CAC in symptomatic populations, but the data are limited by small sample sizes and a paucity of events. Georgiou et al 23 found prognostic value for CAC, but this study was limited by a relatively small number of events (n=30). Two other studies demonstrated significant prognostic value of CAC in symptomatic individuals, but each cohort reported <23 hard events. 24, 25 Although all 3 studies showed CAC to be predictive of cardiovascular events, the small number of hard events has limited the evidence of utility of CAC in symptomatic individuals, as reflected in a Class IIb guideline recommendation for use. 12, 26 Although both CAC and FT had moderate discriminatory ability to predict future cardiovascular events, the respective distributions of events within the groups were quite different. A positive CAC test identified 112 of 133 total events (84%) and 44 of 53 hard events (83%), whereas a positive FT identified 57 of 132 events (43%) of total death, myocardial infarction, and unstable angina and only 33% of hard cardiovascular events (myocardial infarction and cardiovascular death; Table IV in the online-only Data Supplement), resulting in a much higher sensitivity for future cardiovascular events with CAC compared with FT (P<0.001).
In regard to obstructive CAD, a recently published study on 10 037 symptomatic patients who underwent concomitant coronary CTA and CAC scoring revealed that 84% of patients with zero CAC score had no CAD, 13% had nonobstructive stenosis, only 3.5% had ≥50% stenosis, and 1.4% had ≥70% stenosis on coronary CTA. 13 This study demonstrated a very high sensi- tivity for CAC score of zero to rule out obstructive CAD. Overall, 18 studies demonstrated that the presence of any CAC had a pooled sensitivity of 98% for the detection of significant CAD on ICA. 27 CAC has also been shown to accurately risk-stratify symptomatic patients presenting to the emergency department with acute chest pain. Intermediate-risk patients with acute chest pain and no history of CAD commonly have a CAC score of zero with a very low subsequent risk of MACEs or death/myocardial infarction. In these patients with acute chest pain, a meta-analysis found that patients with a CAC score of 0 have a significantly lower risk of future cardiovascular events compared with those with a positive CAC and a very low (<1%/y) rate of both MACEs and hard cardiac events. In this setting, 60% of patients had a CAC score of zero, much higher than in the present study, and were at very low risk and unlikely to benefit from hospital admission or further diagnostic testing. 28 Absence of CAC had a negative predictive value of 99% for ruling out acute coronary syndrome in 4 studies. 28, 29 This was further demonstrated in our cohort, in whom only 9 hard events occurred among 1457 negative (zero score) CAC scans, for an event rate of 0.6%. A normal FT was associated with a 2-fold event rate, with 48 events occurring among 3588 with normal FT, for an event rate of 1.3% ( Figure 3C ).
Although stress testing demonstrated a low sensitivity (48%) for cardiovascular events, the specificity was significantly higher than for CAC testing, especially with the definition of CAC>0 used as the threshold. CAC may have several advantages over FT. Compared with FT, CAC is a rapid, simple test that has no contraindications, is performed on conventional CT systems, incurs little radiation exposure, and is easily interpretable and relatively inexpensive. 29 Given the low prevalence of obstructive CAD in the current populations, the optimal diagnostic strategy may be CAC as an initial test, followed by a second test. Thus, the high sensitivity of CAC for cardiovascular events could potentially be used to rule out patients, and in those with positive CAC scans, a second test with high specificity could be used to determine those at risk of future cardiovascular events. FT is an ideal candidate for such a second test because it provides evidence of ischemia required to guide revascularization. Furthermore, in the PROMISE trial, the CT strategy was associated with a higher proportion of patients newly initiated on aspirin (51% increase), statins (110% increase), and β-blockers (52% greater) compared with FT (P<0.0001 for each), and the patients reporting healthy eating was also higher after coronary CTA (P=0.002). 30 The SCOT-Heart trial (Scottish Computed Tomography of the Heart) also reported more preventive therapies in the CTA arm. 31 Alternatively, the present study, with a high sensitivity of CAC for cardiovascular events, also supports the sequential testing algorithm evaluated in the CRESCENT trial (Calcium Imaging and Selective CT Angiography in Comparison to Functional Testing for Suspected Coronary Artery Disease), 32 a prospective randomized trial that used CAC as a first-line test, advancing to CTA when CAC scores were 1 to 400. This study demonstrated that event-free survival was 96.7% for patients randomized to CT and 89.8% for patients randomized to FT (P<0.011). Furthermore, a tiered CT approach established diagnosis sooner than FT (P<0.0001), resulting in less downstream testing (25% versus 53%; P<0.0001) and lower cumulative diagnostic costs (€369 versus €440; P<0.0001). CRESCENT Investigators concluded, "Incorporating the calcium scan into the diagnostic workup was safe and lowered diagnostic expenses and radiation exposure." In this study, there was no significant difference in stratifying by CAC=0 or defining low risk as CAC <10 (Tables 3  and 4 ). In PROMISE, 19 of 21 patients with zero CAC and cardiovascular events had <70% stenosis on coronary CTA, and hard event rates for CAC zero were far less than 1% annual risk. In the cardiovascular death/myocardial infarction group, there were only 9 events among the 1457 patients followed up with CAC=0. In regard to obstructive disease, this study revealed that of those with zero CAC (n=1457), only 7 (0.5%) had >70% stenosis on CTA (Table IV in the online-only Data Supplement). This very high sensitivity for obstructive disease and cardiovascular events supports the use of a CAC as a first approach, as was done in CRESCENT, with CAC used to exclude further evaluation.
Although CTA has been demonstrated to have higher discriminatory ability than both CAC and FT for CAD, 16, 33, 34 it requires contrast and intravenous access and entails higher cost than both exercise testing and CAC. Hoffmann et al 16 previously demonstrated CTA to have superior prognostic and discriminatory ability to FT. We found that anatomic assessment with coronary CTA provided significantly better prognostic information compared with CAC testing (C index, 0.72 versus 0.67). When test findings were stratified as mildly, moderately, or severely abnormal, HRs for events compared with normal tests increased proportionally for CTA and CAC testing, whereas HRs were higher for CTA (CTA: 2.94, 7.67, and 10.13; all P<0.001; CAC: 1.51 [P=0.147], 3.14, and 3.56 [both P<0.001]). There was a moderate overlap of disease categories between CAC and CTA result groups. Patients with severe CAC had more severe stenosis, and 98% of those with normal CAC had normal coronaries or nonobstructive disease (Table 5) .
Limitations
This analysis represents a post hoc evaluation of CAC testing because the design of the PROMISE trial was CTA versus FT.
14 Furthermore, only 4209 patients underwent CAC scanning whereas 4589 underwent CTA testing in PROMISE. 16 The reason not all patients underwent CAC scanning with CTA is that PROMISE was set up as a pragmatic design, and the exact protocol for CTA was not prespecified but left to the local imaging expert (radiologist or cardiologist). Furthermore, it must be clear that the tests in question (CAC versus FT) render different types of results: anatomic CAD versus FT. No quantification of ischemia (ie, percent left ventricular ischemia) was performed in this study because these are site-read results and only a small minority of clinical sites clinically reported these variables. Because of its pragmatic, real-world design, this study has inherent strengths and limitations of such reports. Future analyses should look at quantitative measures of ischemia on stress imaging and compare them with quantitative anatomic measures (ie, CTA stenosis or CAC).
Conclusions
Among stable patients presenting with suspected CAD, most events occur in patients who do not have inducible myocardial ischemia, as detected by FT. Conversely, CAC=0 can safely exclude future cardiovascular events in symptomatic patients with suspected CAD. Most events occurred in patients with positive CAC scans, and the discriminatory ability of CAC suggests that it may have a role in the initial evaluation of new-onset stable chest pain. However, both approaches have strengths in detecting future cardiovascular events in patients with stable CAD, and a combined tiered approach may be most prudent.
SOURCES OF FUNDING
This project was supported by grants R01HL098237, R01HL098236, R01HL98305, and R01HL098235 from the National Heart, Lung, and Blood Institute. The authors are solely responsible for the design and conduct of this study, all study analyses, the drafting and editing of the article, and its final contents. This article does not necessarily represent the official views of National Heart, Lung, and Blood Institute. Dr Bittner was supported by National Institutes of Health/National Heart, Lung, and Blood Institute 5K24HL113128. 
DISCLOSURES
Dr Budoff reports receiving grants from the National Institutes of Health and General Electric. Dr Ferencik reports receiving grant support from the American Heart Association. Dr Douglas reports receiving grant support from HeartFlow and service on a data and safety monitoring board for GE HealthCare. Dr Hoffmann reports receiving grants from the American College of Radiology Imaging Network and HeartFlow Inc during the conduct of the study and from Siemens Healthcare. The other authors report no conflicts.
